Fevipiprant is primarily used in the treatment of asthma, particularly for patients with severe or uncontrolled asthma who do not respond adequately to standard therapies. It works by targeting and inhibiting the prostaglandin D2 receptor, which plays a key role in inflammation and bronchoconstriction associated with asthma. By blocking this receptor, it helps reduce airway inflammation, improve lung function, and decrease the frequency of asthma exacerbations. It is also being investigated for potential applications in other inflammatory conditions, such as allergic rhinitis and chronic obstructive pulmonary disease (COPD), due to its anti-inflammatory properties.